Novartis AG is hoping to regenerate cartilage in osteoarthritis patients with its first-in-class chondrogenesis inducer LNA043 but will have to prove that its anabolic effects will translate into improvements in joint function and reduce joint replacement to really crack this massively underserved market.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?